ProtonDx's core technology builds on several years of innovative research in diagnostics and sample extractions, fuelled by unique collaborations between engineering, medicine and molecular biology. The spin-out company was founded in 2020 at Imperial College London and is based on Lab-on-Chip diagnostic technology.
The team developed Lacewing, a point-of-care device that detects parasite DNA from a few microliters of finger-prick blood in 15-30 minutes. The team also developed ramps up for Dragonfly, a point-of-care, in vitro diagnostic device that was used at the 2022 Winter Olympics and Commonwealth Games. Today, they are continuing to innovate and develop diagnostics.
Imperial researchers working on ProtonDX:
- Dr Jesus Rodriguez Manzano (Co-Founder and Chief Scientific Officer)
- Professor Pantelis Georgiou (Co-Founder and Director)
- Dr Nick Moser (Co-Founder and Chief Technology Officer)
- Dr Matthew Cavuto (Head of Engineering and Product Development)
- Dr Ivana Pennisi
The Proton DX also utilises the following assays to aid in diagnosing infections.
| Human Assays | Porcine Assays |
|---|---|
|
Skin Infection Viral Panel: Multi-pathogen test for OPV, MPOX, VZV, HSV1, and HSV2. |
Actinobacillus pleuropneumoniae (APP) |
| Respiratory Test Panel: Multi-pathogen test for SARS-CoV-2, Flu A, Flu B, RSV, and HRV |
Glaesserella parasuis (GPS) |
|
Malaria Species Test Panel: Multi-pathogen test for Pf, Pv, Pm, Po, and PK. |
Mycoplasma hyopneumoniae (MH) |
|
Malaria Pan/Pf Test Panel: Multi-patient test for up to 6 patients. |
Pasteurella multocida (PM) |
|
Fever Test Panel: Multi-pathogen test for DENV, CHIKV, YFV, ZIKV, and Malaria Pan/Pf (in preparation). |
Streptococcus suis (SS) |
|
HIV: Multi-patient test for up to 6 patients (in preparation). |
Porcine circovirus (PCV2b and 2d) |
|
Influenza A (sub-typing panel): In preparation. |
Swine influenza (H1N1 2009 and H1N2) |
|
PRRSV |
|
|
Influenza (H1,H3,H5, H7, H9) |
